FREQUENCY OF RECURRENCE AFTER DISCONTINUANCE OF ANTI-CONVULSANT THERAPY IN PATIENTS WITH EPILEPTIC SEIZURES.

作者: P. JUUL-JENSEN

DOI: 10.1111/J.1528-1157.1964.TB03341.X

关键词:

摘要: SUMMARY After a seizure-free period of at least two years, anticonvulsant therapy was withdrawn in 200 patients who had previously epileptic seizures. A follow-up study revealed that the seizures recurred 35% during 2 years and 36.5% 4 after commencement withdrawal. Of recurrences, 50% were seen withdrawal (normally lasting 2–3 months), most remaining cases encountered within first year withdrawal, i.e. greater part which no medication all given. It is not possible to set up clear criteria for withdrawal; but analysis shows presence slow-activity foci or bilateral paroxysms increases risk recurrence. It also found frequency recurrence with age onset epilepsy. Epilepsy known pathogenesis involves slightly increased recurrence, whereas type epilepsy, its severity before length atrophy pneumoencephalography are importance. It concluded should be contemplated only very suitable cases. RESUME La therapeutique anti-convulsivante ete diminuee et enfin interrompue chez epileptiques apes qu'ils soient demeures au moins deux ans sans crise sous son effet. Les crises sont reapparues d'entre eux dans les suivant le de la diminuation medication. Dans moitie des cas pendant periode sevrage proprement dite, qui dure normalement 3 mois; plupart autres elles premiere annee apres medication. II est impossible preciser conditions permettraient decider du moment optimum pour l'interruption traitement un epileptique. II nous cependant apparu que d'activites lentes focalisees ou paroxysmes bilateraux sur l'E.E.G. doivent faire craindre une reapparition l'arret traitement. egalement semble risque voir reapparaitre augmentait avec l'âge sujet debut epilepsie. Par contre l'epilepsie, sa severite, l'existence d'une atrophie cerebrale visible pneumoencephalographie duree ne semblent jouer aucun role. De ce precede on peut tirer conclusion doit etre envisagee tres appropries.

参考文章(9)
H. H. Merritt, Medical Treatment in Epilepsy BMJ. ,vol. 1, pp. 666- 669 ,(1958) , 10.1136/BMJ.1.5072.666
Matthew T. Moore, PULMONARY CHANGES IN HYDANTOIN THERAPY Journal of the American Medical Association. ,vol. 171, pp. 1328- 1333 ,(1959) , 10.1001/JAMA.1959.03010280052013
R. R. J. STROBOS, Prognosis in convulsive disorders. JAMA Neurology. ,vol. 1, pp. 216- 225 ,(1959) , 10.1001/ARCHNEUR.1959.03840020090011
Melvin D. Yahr, EVALUATION OF STANDARD ANTICONVULSANT THERAPY IN THREE HUNDRED NINETEEN PATIENTS JAMA: The Journal of the American Medical Association. ,vol. 150, pp. 663- 667 ,(1952) , 10.1001/JAMA.1952.03680070033009
E. L. GIBBS, DISAPPEARANCE AND MIGRATION OF EPILEPTIC FOCI IN CHILDHOOD Archives of Pediatrics & Adolescent Medicine. ,vol. 88, pp. 596- 603 ,(1954) , 10.1001/ARCHPEDI.1954.02050100598005
ERNA L. GIBBS, FREDERIC A. GIBBS, Good prognosis of mid-temporal epilepsy. Epilepsia. ,vol. 1, pp. 448- 453 ,(1959) , 10.1111/J.1528-1157.1959.TB04279.X
DOROTHY T. KRIEGER, Effect of diphenylhydantoin on pituitary-adrenal interrelations. The Journal of Clinical Endocrinology and Metabolism. ,vol. 22, pp. 490- 493 ,(1962) , 10.1210/JCEM-22-5-490
Juul-Jensen P, EPILEPSY. A CLINICAL AND SOCIAL ANALYSIS OF 1020 ADULT PATIENTS WITH EPILEPTIC SEIZURES. Acta Neurologica Scandinavica. ,vol. 40, ,(1964)